Elvina Almuradova/X
May 31, 2025, 07:32
Elvina Almuradova: HER2+ T1micN0 BC-a long-debated gray zone
Elvina Almuradova, Associate Professor of Oncology at the European Institute of Oncology, shared a post on X:
“HER2+ T1micN0 BC-a long-debated gray zone.
MSKCC study (n=213)
Key findings:
No difference in invasive disease-free survival (iDFS) between patients with 1–4 vs. ≥5 microinvasive foci
No clear iDFS benefit from adjuvant chemotherapy + HER2-targeted therapy (CT/H2TT) in patients with ≥5 foci
And yet, prognosis was excellent overall, with a 5-year iDFS of 95%
More treatment ≠ , better outcome?”
Title: Treatment patterns and clinical outcomes of patients with HER2-positive T1micN0 breast cancer: a single-center analysis
Authors: Celine Yeh, Rachel Han, Abha Kulkarni, Charlie White, Yuan Chen, Matthew G. Hanna, Edi Brogi, Andrew D. Seidman
You can read the Full Article on Nature Partner Journals Breast Cancer
More posts featuring Elvina Almuradova.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 31, 2025, 07:32
May 31, 2025, 07:20
May 31, 2025, 07:14
May 31, 2025, 06:50
May 31, 2025, 06:42
May 31, 2025, 05:11